Overview

Safety Study of Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies

Status:
Completed

Trial end date:
2019-01-01

Target enrollment:

Participant gender:

Summary

In this study, MGCD265, a new anticancer drug under investigation, is given daily to patients with advanced malignancies to study its safety profile.

Phase:

Phase 1

Details

Lead Sponsor:

Mirati Therapeutics Inc.